MaxCyte Regains Nasdaq Compliance, Resolving Bid Price Deficiency
MXCT sits 77% above its 52-week low of $0.643.
Summary
MaxCyte, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving the previously disclosed non-compliance issue.
Key Events · Corporate Governance and Compliance · MXCT
-
Nasdaq Compliance Regained
MaxCyte received notification from Nasdaq that its common stock has traded at or above $1.00 for 10 consecutive business days, from May 27, 2026 to June 9, 2026.
-
Delisting Risk Averted
This action closes the matter of non-compliance with Nasdaq Listing Rule 5450(a)(1), removing the immediate threat of delisting that was disclosed on March 20, 2026.
Analysis · MXCT · Industrial Applications And Services
This 8-K filing is highly important as it resolves a critical compliance issue that could have led to the company's delisting from Nasdaq. The company had previously received a notice of non-compliance due to its stock trading below $1.00. Regaining compliance removes a significant overhang and a major risk factor, which is crucial for investor confidence and the company's ability to access capital markets, especially given its recent financial struggles and cost-cutting efforts.
At the time of this filing, MXCT was trading at $1.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $122.1M. The 52-week trading range was $0.64 to $2.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.